A Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib?

J Endocr Soc. 2024 May 7;8(7):bvae092. doi: 10.1210/jendso/bvae092. eCollection 2024 May 23.
No abstract available

Keywords: anlotinib; axitinib; metastatic; paraganglioma; pheochromocytoma; sunitinib.

Publication types

  • Comment